MUC1 BCMA CAR-T cells

MUC1 BCMA CAR-T cells are an experimental autologous cell therapy designed to treat multiple myeloma by dual-targeting tumor antigens. The production process involves a unique two-step approach: first, patient-derived T cells are stimulated ex vivo with MUC1 peptide-loaded autologous peripheral blood mononuclear cells (PBMCs) to enrich for T cells with endogenous MUC1-specific T-cell receptors (TCRs). Subsequently, these MUC1-activated T cells are engineered with a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA), incorporating a 4-1BB costimulatory domain. This dual-specificity (MUC1 TCR + BCMA CAR) is intended to enhance T-cell potency, proliferation, and persistence while mitigating the risk of tumor relapse through antigen escape. Preclinical data presented by researchers at the Mayo Clinic indicate that these dual-targeted cells exhibit superior tumor-killing capacity and transcriptomic profiles associated with enhanced effector function compared to conventional BCMA CAR-T cells.

Other names

MUC1 TCR+BCMA CAR+ T cellsMUC1-activated BCMA CAR-T cellsMUC-1-activated BCMA CAR-T cellsMUC 1-activated BCMA CAR-T cells